Nyxoah Investor Relations Material

Nyxoah S.A. is a medical technology company that specializes in developing and commercializing innovative treatments for Obstructive Sleep Apnea (OSA). The company's flagship product, the Genio system, offers a patient-centric and CE-Marked hypoglossal neurostimulation therapy designed to treat moderate to severe cases of OSA. This therapy serves as an alternative for patients who are unable or unwilling to tolerate Continuous Positive Airway Pressure (CPAP) treatments. The company is headquartered in Mont-Saint-Guibert, Belgium, and its shares are listed on the NASDAQ.